Background, summary
Brian Rifkin
Chimerism and Immune Tolerance: Can We Says ...

This week, we will discuss the use of creating chimeras to induce immune tolerance and its potential to decrease or eliminate the need for immunosuppression in kidney transplant recipients.

Chimerism and Immune Tolerance: Can We Says Goodbye to Immunosuppression?
Meta
joel topf
NephJC 2025 Fall Pledge Drive

Help keep NephJC a vital, original, and unbiased source of medical education.

NephJC 2025 Fall Pledge Drive
Background, summary
Brian Rifkin
PREVENT, Detect, Treat: What’s New in the 2025 ...

This week, we will discuss the AHA/ACC 2025 hypertension guideline update. Wow, have eight years flown by?

PREVENT, Detect, Treat: What’s New in the 2025 Hypertension Toolkit
Background
swapnil hiremath
In ESRD is spironolactone an overACHIEVEr?

This week, we will discuss the ACHIEVE trial. Will spironolactone achieve CV benefits in ESRD?

In ESRD is spironolactone an overACHIEVEr?
Background
joel topf
#NephJC Summer Bookclub: Everything is ...

The summer book club started in 2015, with one of the best books we have done in book club, Atul Gawande's Being Mortal. I think it should be required reading for all physicians. So now, in 2025, it is the NephJC Summer Book’s tenth anniversary (which represents our eleventh book). The history has been rich:

#NephJC Summer Bookclub: Everything is Tuberculosis by John Green

testing 2

Freely Filtered does TESTING-2

Episode 048: TESTING is the latest IgA nephropathy trial and it is the comeback kid of nephrology trials. From a trial that was halted because of excess adverse events to a safe and effective therapy with just a few tweeks. Amazing turn around. Join the Filtrate as we put TESTING to the test with study author Sean Barbour.

Listen

Ten Tweets does TESTING 2.0

Did you miss the TESTING reboot discussion? No worries, we have you covered here: